<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234298</url>
  </required_header>
  <id_info>
    <org_study_id>SPD489-320</org_study_id>
    <nct_id>NCT01234298</nct_id>
  </id_info>
  <brief_title>SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia</brief_title>
  <acronym>NSS</acronym>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to
      placebo when given as adjunctive therapy to antipsychotic medication in clinically stable
      adults with persistent predominant negative symptoms of schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was discontinued due to non-safety related business prioritization decisions
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Symptom Assessment (NSA-16) total score</measure>
    <time_frame>up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Negative Symptoms of Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SPD489 Low-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPD489 High-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD489 Low-Dose</intervention_name>
    <description>SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks</description>
    <arm_group_label>SPD489 Low-Dose</arm_group_label>
    <other_name>Vyvanse, Lisdexamfetamine dimesylate, LDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD489 High-Dose</intervention_name>
    <description>SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks</description>
    <arm_group_label>SPD489 High-Dose</arm_group_label>
    <other_name>Vyvanse, Lisdexamfetamine dimesylate, LDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule taken once-daily for up to 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has diagnosis of schizophrenia for at least 2 years

          -  Subject has persistent predominant negative symptoms

          -  Subject has 2 or more persistent predominant negative symptoms (affective flattening,
             alogia, avolition apathy, and anhedonia-asociality) determined to have been present
             for at least 6 months

          -  Subject is maintained on antipsychotic monotherapy or polytherapy with no more than 2
             antipsychotic medications

          -  Subject has been clinically stable and is in the non-acute phase of illness

        Exclusion Criteria:

          -  Subject has clinically notable positive symptoms

          -  Subject is considered to be treatment refractory

          -  Subject has current history of substance abuse/dependance

          -  Subject is considered a suicide risk or risk to harm others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

